# Silence Therapeutics plc: financial statements, quarterly

SLN · Nasdaq · CIK 1479615 · [Healthcare](/sectors/healthcare.md)

Pages: [Overview](/companies/sln.md) · [Financials](/companies/sln/financials.md) · [Filings](/companies/sln/filings.md) · [Insiders](/companies/sln/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sln/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [15.7](/filings/0000950170-25-066439.md) | [0.8](/filings/0000950170-25-104593.md) | [1.5](/filings/0001193125-25-268116.md) | [25.3 d](/filings/0001193125-26-092591.md) | [0.1](/filings/0001193125-26-210446.md) | [0.2](/filings/0001193125-26-341248.md) | [0.2](/filings/0001193125-25-268116.md) | [0.0 d](/filings/0001193125-26-092591.md) | [0.4](/filings/0001193125-26-210446.md) | [0.0](/filings/0001193125-26-341248.md) |
| Cost of revenue | $m | [2.8](/filings/0000950170-25-066439.md) | [3.3](/filings/0000950170-25-104593.md) | [3.6](/filings/0001193125-25-268116.md) | [2.0 d](/filings/0001193125-26-092591.md) | [0.1](/filings/0001193125-26-210446.md) | [0.1](/filings/0001193125-26-341248.md) | [0.1](/filings/0001193125-25-268116.md) | [0.0 d](/filings/0001193125-26-092591.md) | [0.0](/filings/0001193125-26-210446.md) | [0.0](/filings/0001193125-26-341248.md) |
| Gross profit | $m | [12.9](/filings/0000950170-25-066439.md) | [(2.6)](/filings/0000950170-25-104593.md) | [(2.1)](/filings/0001193125-25-268116.md) | [23.3 d](/filings/0001193125-26-092591.md) | [0.1](/filings/0001193125-26-210446.md) | [0.1](/filings/0001193125-26-341248.md) | [0.1](/filings/0001193125-25-268116.md) | [0.0 d](/filings/0001193125-26-092591.md) | [0.4](/filings/0001193125-26-210446.md) | [0.0](/filings/0001193125-26-341248.md) |
| Research and development | $m | [11.8](/filings/0000950170-25-066439.md) | [13.8](/filings/0000950170-25-104593.md) | [20.2](/filings/0001193125-25-268116.md) | [22.1 d](/filings/0001193125-26-092591.md) | [20.8](/filings/0001193125-26-210446.md) | [17.6](/filings/0001193125-26-341248.md) | [20.5](/filings/0001193125-25-268116.md) | [8.7 d](/filings/0001193125-26-092591.md) | [9.1](/filings/0001193125-26-210446.md) | [9.1](/filings/0001193125-26-341248.md) |
| Operating income | $m | [(5.6)](/filings/0000950170-25-066439.md) | [(23.4)](/filings/0000950170-25-104593.md) | [(30.0)](/filings/0001193125-25-268116.md) | [(4.4) d](/filings/0001193125-26-092591.md) | [(28.4)](/filings/0001193125-26-210446.md) | [(24.0)](/filings/0001193125-26-341248.md) | [(26.2)](/filings/0001193125-25-268116.md) | [(12.5) d](/filings/0001193125-26-092591.md) | [(15.7)](/filings/0001193125-26-210446.md) | [(13.9)](/filings/0001193125-26-341248.md) |
| Income tax | $m | [0.2](/filings/0000950170-25-066439.md) | [0.2](/filings/0000950170-25-104593.md) | [0.0](/filings/0001193125-25-268116.md) | [0.3 d](/filings/0001193125-26-092591.md) | [0.0](/filings/0001193125-26-210446.md) | [0.0](/filings/0001193125-26-341248.md) | [0.0](/filings/0001193125-25-268116.md) | [0.0 d](/filings/0001193125-26-092591.md) | [0.0](/filings/0001193125-26-210446.md) | [0.0](/filings/0001193125-26-341248.md) |
| Net income | $m | [(2.3)](/filings/0001193125-25-268116.md) | [(19.8)](/filings/0001193125-25-268116.md) | [(35.5)](/filings/0001193125-25-268116.md) | [12.3 d](/filings/0001193125-26-092591.md) | [(28.5)](/filings/0001193125-26-341248.md) | [(27.4)](/filings/0001193125-26-341248.md) | [(21.0)](/filings/0001193125-25-268116.md) | [(11.8) d](/filings/0001193125-26-092591.md) | [(15.0)](/filings/0001193125-26-341248.md) | [(12.3)](/filings/0001193125-26-341248.md) |
| Diluted EPS | $ per share | [(0.02)](/filings/0000950170-25-066439.md) | [(0.14)](/filings/0000950170-25-104593.md) | [(0.25)](/filings/0001193125-25-268116.md) | not reported | [(0.20)](/filings/0001193125-26-210446.md) | [(0.19)](/filings/0001193125-26-341248.md) | [(0.15)](/filings/0001193125-25-268116.md) | not reported | [(0.11)](/filings/0001193125-26-210446.md) | [(0.09)](/filings/0001193125-26-341248.md) |
| Basic EPS | $ per share | [(0.02)](/filings/0000950170-25-066439.md) | [(0.14)](/filings/0000950170-25-104593.md) | [(0.25)](/filings/0001193125-25-268116.md) | not reported | [(0.20)](/filings/0001193125-26-210446.md) | [(0.19)](/filings/0001193125-26-341248.md) | [(0.15)](/filings/0001193125-25-268116.md) | not reported | [(0.11)](/filings/0001193125-26-210446.md) | [(0.09)](/filings/0001193125-26-341248.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2022 (2022-12-31) | FY2023 (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [68.8](/filings/0000950170-25-029129.md) | not reported | not reported | not reported | [121](/filings/0001193125-26-092591.md) | [64.9](/filings/0000950170-25-066439.md) | [41.7](/filings/0000950170-25-104593.md) | [82.0](/filings/0001193125-25-268116.md) | [11.3](/filings/0001193125-26-341248.md) | [5.7](/filings/0001193125-26-210446.md) | [72.1](/filings/0001193125-26-341248.md) |
| Current assets | $m | [96.7](/filings/0000950170-24-030519.md) | [103](/filings/0000950170-25-029129.md) | not reported | not reported | not reported | [187](/filings/0001193125-26-092591.md) | [170](/filings/0000950170-25-066439.md) | [149](/filings/0000950170-25-104593.md) | [134](/filings/0001193125-25-268116.md) | [119](/filings/0001193125-26-341248.md) | [103](/filings/0001193125-26-210446.md) | [94.3](/filings/0001193125-26-341248.md) |
| Total assets | $m | not reported | [119](/filings/0000950170-25-029129.md) | not reported | not reported | not reported | [203](/filings/0001193125-26-092591.md) | [185](/filings/0000950170-25-066439.md) | [165](/filings/0000950170-25-104593.md) | [147](/filings/0001193125-25-268116.md) | [131](/filings/0001193125-26-341248.md) | [115](/filings/0001193125-26-210446.md) | [106](/filings/0001193125-26-341248.md) |
| Current liabilities | $m | [21.9](/filings/0000950170-24-030519.md) | [22.3](/filings/0000950170-25-029129.md) | not reported | not reported | not reported | [16.8](/filings/0001193125-26-092591.md) | [19.3](/filings/0000950170-25-066439.md) | [14.8](/filings/0000950170-25-104593.md) | [17.4](/filings/0001193125-25-268116.md) | [13.6](/filings/0001193125-26-341248.md) | [10.5](/filings/0001193125-26-210446.md) | [12.7](/filings/0001193125-26-341248.md) |
| Total liabilities | $m | not reported | [97.5](/filings/0000950170-25-029129.md) | not reported | not reported | not reported | [68.6](/filings/0001193125-26-092591.md) | [72.6](/filings/0000950170-25-066439.md) | [71.1](/filings/0000950170-25-104593.md) | [72.7](/filings/0001193125-25-268116.md) | [69.1](/filings/0001193125-26-341248.md) | [65.7](/filings/0001193125-26-210446.md) | [67.9](/filings/0001193125-26-341248.md) |
| Shareholders' equity | $m | [27.2](/filings/0000950170-25-029129.md) | [22.0](/filings/0001193125-26-092591.md) | [157](/filings/0001193125-25-268116.md) | [143](/filings/0001193125-25-268116.md) | [127](/filings/0001193125-25-268116.md) | [134](/filings/0001193125-26-341248.md) | [113](/filings/0001193125-26-341248.md) | [94.2](/filings/0001193125-26-341248.md) | [74.1](/filings/0001193125-25-268116.md) | [62.3](/filings/0001193125-26-341248.md) | [49.4](/filings/0001193125-26-341248.md) | [38.5](/filings/0001193125-26-341248.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: ifrs-full:CurrentAssets, us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: ifrs-full:CurrentLiabilities, us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(9.1)](/filings/0000950170-25-066439.md) | [(5.4) d](/filings/0000950170-25-104593.md) | [(25.6) d](/filings/0001193125-25-268116.md) | [(27.5) d](/filings/0001193125-26-092591.md) | [(12.3)](/filings/0001193125-26-210446.md) | [(21.8) d](/filings/0001193125-26-341248.md) | [(10.9) d](/filings/0001193125-25-268116.md) | [(17.3) d](/filings/0001193125-26-092591.md) | [(15.6)](/filings/0001193125-26-210446.md) | [1.5 d](/filings/0001193125-26-341248.md) |
| Capital expenditure | $m | [0.0](/filings/0000950170-25-066439.md) | [0.1 d](/filings/0000950170-25-104593.md) | [0.1 d](/filings/0001193125-25-268116.md) | [0.1 d](/filings/0001193125-26-092591.md) | [0.0](/filings/0001193125-26-210446.md) | [0.0 d](/filings/0001193125-26-341248.md) | [0.0 d](/filings/0001193125-25-268116.md) | [0.0 d](/filings/0001193125-26-092591.md) | [0.0](/filings/0001193125-26-210446.md) | [0.0 d](/filings/0001193125-26-341248.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [132](/filings/0000950170-25-066439.md) | [140](/filings/0000950170-25-104593.md) | [141](/filings/0001193125-25-268116.md) | [142](/filings/0001193125-26-210446.md) | [142](/filings/0001193125-26-341248.md) | [142](/filings/0001193125-25-268116.md) | [142](/filings/0001193125-26-210446.md) | [142](/filings/0001193125-26-341248.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 141,740,037 at 2026-07-31, from the cover of the [10-Q filed 2026-08-10](/filings/0001193125-26-341248.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.